Show simple item record

dc.contributor.author Cainelli, F.
dc.contributor.author Vallone, A.
dc.date.accessioned 2009-12-10T09:34:10Z
dc.date.available 2009-12-10T09:34:10Z
dc.date.issued 2009
dc.identifier.citation Cainelli, F. & Vallone, A. (2009) Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi’s sarcoma, Biologics: Targets & Therapy, vol. 3, pp. 385–390 en_US
dc.identifier.issn 1177-5491 (online)
dc.identifier.issn 1177-5475 (Print)
dc.identifier.uri http://hdl.handle.net/10311/419
dc.description.abstract Kaposi’s sarcoma is a vascular tumor linked to the presence of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus-8) and the incidence of which has increased considerably the world over after the onset of the human immunodeficiency virus (HIV) pandemic. Antiretroviral therapy combined with cytotoxic agents has been established as the treatment of choice in the past 10 years. Among chemotherapeutic agents, pegylated liposomal doxorubicin has become the preferred one for patients with HIV-associated Kaposi’s sarcoma in Western countries. The drug in this formulation localizes better to the tumor and has higher efficacy. Skin toxicity, mucositis, and leukopenia/neutropenia are the main side effects. Hepatotoxicity and mild cardiotoxicity are observed less frequently. Pegylated liposomal doxorubicin impacts favorably on quality of life. Although cost effective in Western countries, the drug is less so in developing countries. en_US
dc.language.iso en en_US
dc.publisher Dove Medical Press Ltd. http://www.dovepress.com/biologics-targets--therapy-journal en_US
dc.subject pegylated liposomal doxorubicin en_US
dc.subject Kaposi’s sarcoma en_US
dc.subject HIV infection en_US
dc.title Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi’s sarcoma en_US
dc.type Published Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search UBRISA


Advanced Search

Browse

My Account